 |
|
|
|||||
A group of masked thieves stole about $7,000 worth of Labubu dolls from a Los Angeles-area store this week, authorities said.The incident took place early Wednesday morning at a store in La Puente, a city about 18 miles (29 kilometers) east of Los Angeles, the LA County Sheriff’s Department said. The department said the suspects used a stolen Toyota Tacoma in the incident, which was recovered shortly afterward. The agency said it was investigating the case and did not have additional information.Labubu dolls, created by Hong Kong-born artist Kasing Lung, have become a popular collectible item a decade after the toothy monsters were first introduced.Toy vendor One Stop Sales said in an Instagram post that the thieves took all of the store’s inventory and trashed the establishment. The store posted surveillance footage showing a group of people wearing hoodies and face coverings breaking in. The suspects are seen shuffling through items and carrying boxes out of the shop.“We are still in shock,” the store said in its post, urging people to help find the thieves. This story has been updated to correct the store’s name. It is One Stop Sales, not One Stop Shop. Associated Press
Category:
E-Commerce
In Novo Nordisks legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profile telehealth company continues to sell compounded versions of Wegovy at lower prices, testing the limits of federal restrictions on such copies and contributing to weaker sales growth for Novo. In June, Novo accused Hims of violating its intellectual property and endangering patients, scrapping a brief arrangement enabling them to sell Wegovy directly to consumers and raising expectations of litigation. A Novo spokesperson said the Danish drugmaker was not ruling out further legal action after announcing new lawsuits against 14 small pharmacies, telehealth providers and weight-loss clinics this week, but declined to comment on Hims. The drugmaker has filed more than 130 cases in 40 U.S. states. A spokesperson for Hims defended personalization of medicines as the future of healthcare, saying patients and providers use their platform to make clinical decisions. “Investors are happy to see Novo getting more aggressive on the litigation front, but remain puzzled as to why they havent confirmed that they are filing or have filed litigation against Hims yet,” said Barclays analyst Emily Field. Legal experts say Novos expanding litigation against smaller telehealth players could add pressure on a company like Hims to negotiate a settlement or help the drugmaker test out strategies. At the same time, the fact that Novo and Hims had a prior collaboration may complicate legal action. “Business happens in the shadow of the law,” said Robin Feldman, a professor at UC Law San Francisco who has written books on the pharmaceutical industry and its intellectual property battles. “Sometimes companies file against smaller players as a shot across the bow, a way to rattle the larger players.” The U.S. Food and Drug Administration set a May 22 deadline for compounding pharmacies to cease mass-producing copies of Wegovy, a practice allowed only when a drug is in shortage. Hims says it still offers personalized versions of Wegovy, in doses not manufactured by Novo, that better suit individual patient needs. The telehealth provider argues that individualized dosing remains legal under compounding rules. Compounding laws are just vague enough to allow for different interpretations, and the interpretation that matters that of the courts has not been provided to our knowledge, said TD Cowen analyst Michael Nedelcovych.Novos cases against smaller compounders could shape how courts interpret those boundaries, said Gaston Kroub, a partner at patent litigation firm Kroub, Silbersher & Kolmykov. This is an untested set of affairs, said Kroub. If you want to train for a heavyweight championship fight, you start sparring with lighter opponents.In addition to trademark infringement, Novo has accused pharmacies of steering people toward compounded Wegovy by interfering with the relationship between clinicians and patients.Josh Gerben, an intellectual property attorney, said the fact that Hims and Novo had a prior business relationship will complicate any claim Novo could bring. Maggie Fick and Diana Novak Jones, Reuters
Category:
E-Commerce
New Jersey-based DermaRite Industries has announced a voluntary recall of individual lots of soap and skincare products due to microbial contamination, which has been identified as Burkholderia cepacia, the company said last week. The bacterium can cause serious and life-threatening infections. The Food and Drug Administration (FDA) published a recall announcement on August 9. Impacted products include over-the-counter (OTC) antiseptic lotion soaps, external analgesics, antimicrobial foam soaps, and antiseptic cleansers. The following products are included in the recall: OTC Healthcare antiseptic lotion soap DermaKleen OTC External Analgesic DermaSarra OTC Antimicrobial foam soap KleenFoam OTC Antiseptic cleanser PeriGiene The FDA recall notice includes a list of impacted products with their lot numbers, expiration dates, reorder numbers, product descriptions, and product labels. The recalled products were distributed nationwide in the United States and Puerto Rico. You can also find full-color images of the impacted product labels on DermaRite’s website. The company says it has not received any reports of adverse events related to the recall. Bacterial infection could cause life-threatening sepsis According to a “risk statement” published by DermaRite, the contaminated products may be used by immunosuppressed individuals and people caring for immunosuppressed individuals. Burkholderia cepacia can cause serious, life-threatening infections, according to the Centers for Disease Control and Prevention (CDC). While healthy individuals with minor skin lesions are only likely to experience local infections, people with weakened immune systems are more at risk. For immunosuppressed individuals, the infection is more likely to spread into the bloodstream and could lead to life-threatening sepsis. Sepsis can cause extensive inflammation throughout the body and cause tissue damage, organ failure, and death. Consumers should destroy impacted products DermaRite alerted distributors and customers to the voluntary recall by email and told them to examine their inventory and destroy all affected products immediately. If you have questions about the recall, contact Mary Goldberg by calling 973-569-9000 x104 Monday through Friday, 9:00 am to 5:00 pm EST or by emailing voluntary.action@dermarite.com. If you have experienced problems related to using the impacted products, contact a healthcare provider. Report any adverse reactions experienced as a result of using these products to the FDAs MedWatch Adverse Event Reporting program. You can file a report online, download a reporting form, or call 1-800-332-1088 to request a reporting form to submit by fax or mail.
Category:
E-Commerce
All news |
||||||||||||||||||
|
||||||||||||||||||